Skip to main content

Support from Joan and Don Beall will sustain two UCI MIND programs

By Carousel Slider, In the News

Irvine, Calif., Jan. 31, 2023 — Sustained support from philanthropists Joan and Don Beall to the the Institute for Memory Impairments and Neurological Disorders will allow for the continuation of an educational outreach program in Orange County high schools and the creation of a new research award for an early career researcher. “We are grateful for the Beall’s leadership, involvement and increased support of $100,000 a year for our educational and research programs,” said Joshua Grill, director of UCI MIND. “Support like theirs is critical to the institute’s mission and demonstrates the trust and commitment of the local community in…

Read More

UCI MIND Faculty leads study to model sporadic Alzheimer’s disease in degus

By Carousel Slider, In the News

UCI School of Medicine highlighted innovative research performed in the lab of Xiangmin Xu, PhD, UCI MIND faculty member and professor and Chancellor’s Fellow of anatomy and neurobiology in the UCI School of Medicine.  Dr. Xu and colleagues have found that sporadic Alzheimer’s disease can be modeled in a non-murine rodent called the Chilean degu. “Our findings, taken together, show spontaneous AD-like correlative phenotypes in cognitive performance and neuropathology in aged, outbred degus. This supports that aged degus are a useful and practical model of natural sporadic AD.” Xiangmin Xu Read the article in the February edition of the UCI School…

Read More

FDA decides not to grant accelerated approval to donanemab

By Carousel Slider, Commentary, In the News

In a somewhat surprising move, the US Food and Drug Administration (FDA) has declined to grant accelerated approval to Eli Lilly’s donanemab Read the full press release from Eli Lilly here Like aducanumab and lecanemab, which were previously granted accelerated approval by the FDA, donanemab is a monoclonal antibody treatment against the beta amyloid protein that accumulates in the brain of a person with Alzheimer’s disease. Eli Lilly published very promising results for donanemab in 2021, which included demonstration that donanemab could lower amyloid levels in the brain of people with mild cognitive impairment and mild dementia (the basis for…

Read More

Joshua Grill quoted in a National Geographic article about lecanemab

By Carousel Slider, In the News

The recent FDA approval of lecanemab has generated a lot of buzz in recent days and UCI MIND director, Joshua Grill, PhD has been asked to comment in various highly visible media outlets including the Washington Post and today, in National Geographic.  Related posts: Cell therapy: a new frontier in Parkinson’s disease After decades of research into the causes and treatment of Parkinson’s disease, UCI Health neurologist Dr. Claire Henchcliffe is hopeful that a new cell therapy can finally bring meaningful relief to patients with the progressive neurodegenerative movement disorder. A national expert on Parkinson’s disease, she is one of a small group of…

Read More

Healthy, Drug-Resistant Microglia Reinvigorate Mouse Brain

By Carousel Slider, In the News

UCI MIND faculty member and professor, Mathew Blurton-Jones, PhD, is featured in AlzForum for his lab’s recent collaborative work on creating a new strain of resistant microglia. Lead author and graduate student in the Blurton-Jones lab, Jean Paul Chadarevian, along with collaborators at the University of Pennsylvania published their innovative work in Journal of Experimental Medicine in the December 2022 issue. Read the full article here > Related posts: UCI receives renewal of designation as Huntington’s Disease Society of America Center of Excellence Renewal recognizes UCI’s dedication to patient care and active engagement in research to develop new therapeutic approaches…

Read More

FDA grants accelerated approval to lecanemab

By Carousel Slider, Commentary, In the News

Related posts: More healthy behaviors = lower risk of Alzheimer’s, research shows UCI MIND #InTheNews   @Seniors Matter – Feb. 9, 2022 “People who engaged in more healthy behaviors had a lower risk than people with fewer because all of these things matter, and when it comes to brain-healthy behaviors, more is more!” said Joshua Grill, PhD, a professor of psychiatry and… Inside the brain: The role of neuropathology in Alzheimer’s disease research 90+ Study: Learning from the oldest-old Researchers can learn a lot about how Alzheimer’s develops by studying people at increased risk. People older than age 90, or…

Read More

Alzheimer’s research in people with Down syndrome benefits all

By Carousel Slider, Commentary, In the News

UCI MIND Faculty Member Elizabeth Head, PhD was featured in the Akron Beacon Journal: I recently interviewed Dr. Elizabeth Head, a [professor and] neuropathology core co-investigator at the Alzheimer’s Disease Research Center at University of California, Irvine. While she collaborates with researchers studying Alzheimer’s in the general population, her research is focused specifically on the Down syndrome population. Her team and others are conducting longitudinal studies, in which volunteers with Down syndrome participate for many years, discovering relevant data that are the building blocks for future treatments. Read the full article here > Related posts: UCI Magazine features UCI MIND…

Read More

Two New Stabs at Vaccinating People Against Pathologic Tau

By Carousel Slider, Commentary, In the News

The work of our faculty, researchers, and collaborators was highlighted in a recent Alzforum article on anti-tau vaccines. AC Immune updates Phase 1b/2 comparison of two anti-#tau vaccines. A liposomal vaccine prompted #antibody response against phospho-tau. Preclinical data bode well for another tau vaccine; first trial slated for next year. Read more > Related posts: Study links early life adversity, microglia dysfunction, to aberrant adult stress responses, mental illness “Much of neuroscience and study of brain diseases has focused on the brain’s neurons. This study highlights that in addition to neurons, other brain cells, and especially immune cells, play crucial…

Read More

Dare We Say Consensus Achieved: Lecanemab Slows the Disease

By Carousel Slider, Commentary, In the News

UCI MIND Director Joshua Grill, PhD is featured in and comments on Alzforum’s report on “convincing and noteworthy” lecanemab results. The slightly larger effect on [activities of daily living] ADLs caught the interest of some scientists, since these can feel most important to participants. “[This] indicates that patients and families could benefit from slowing of observable functional worsening,” Joshua Grill of the University of California, Irvine, wrote to Alzforum (full comments below). Read his commentary here > Read the full article here > Related posts: Determining if Dementia Is Uniquely Human Discover Magazine: Aging dogs can develop canine cognitive dysfunction (CCD), sometimes…

Read More

MIND Matters | Quarterly Newsletter | Fall 2022

By Commentary, Community Events, COVID-19, In the News, Participants

Message from the Director Dear Friends of UCI MIND, As the fall MIND Matters newsletter goes to print, many of us are preparing to travel to San Francisco for the annual Clinical Trials in Alzheimer’s Disease (CTAD) meeting, where we will hear important results from recently completed Phase 3 clinical trials of potential new therapies for Alzheimer’s disease (AD). This includes trials of lecanemab (page 1) as well as other treatments. The topline results for lecanemab announced by the trial sponsors are exciting and suggest that lecanemab may slow the progression of AD. The availability of treatments to slow the…

Read More